

**Amendment #2
to RFP-NIH-NIAID-DAIDS-03-13**

"HLA Typing and Epitope Mapping Relative to HIV Vaccine Design"

Amendment to Solicitation No.: NIH-NIAID-DAIDS-03-13

Amendment No.: Two (2)

Amendment Date: August 30, 2002

RFP Issue Date: May 30, 2002

Proposal Due Date: October 1, 2002 at 4:00 PM Local Time

Issued By: Paul D. McFarlane
Senior Contracting Officer
NIH/NIAID
Contract Management Branch
6700-B Rockledge Drive
Room 2230, MSC 7612
Bethesda, Maryland 20892-7612

Point of Contact: Scott Drega, Contract Specialist
Sdrega@niaid.nih.gov

Name and Address of Offeror: To All Offerors

Purpose of Amendment: See below.

The purpose of this amendment is to provide all Offerors with a clarification regarding page limitations for the proposals. Language in the Notes to Offerors conflicted with the Proposal Submission instructions and this Amendment provides clarification on that issue. The proposal due date and time remain unchanged.

NOTE # 1 TO OFFEROR is hereby amended as follows:

Delete: "The entire submission (technical, business and appendixes) should not exceed 200 single-spaced pages and must conform in format to the specifications described in the NIH PHS 398 application."

Offerors should note that the Page Limitations for the proposals are stated in the RFP under the section entitled "HOW TO PREPARE AND SUBMIT AN ELECTRONIC PROPOSAL." The page limitation language is as follows:

PAGE LIMITS -- THE TECHNICAL PROPOSAL IS LIMITED TO, NOT-TO-EXCEED Two-hundred (200) TOTAL PAGES, [INCLUDING: Appendices, Attachments, Operating Manuals, Non-Scannable Figures or Data, Letters of Intent, etc.] The **NARRATIVE PORTION OF THE TECHNICAL PROPOSAL IS LIMITED TO, NOT-TO-EXCEED Fifty (50) PAGES. ANY PORTIONS OF YOUR TECHNICAL PROPOSAL NOT AVAILABLE ELECTRONICALLY ARE ALSO CONSIDERED TO BE INCLUDED IN THE TOTAL PAGE LIMITATION. PAGES IN EXCESS OF THIS LIMITATION WILL BE REMOVED FROM THE PROPOSAL AND WILL NOT BE READ OR EVALUATED.**

Note that although no page limit has been placed on the **Business Proposal**, Offerors are encouraged to limit its content to only those documents necessary to provide adequate support for the proposed costs.

Except as provided herein, all terms and conditions of the RFP document NIH-NIAID-DAIDS-03-13 remain unchanged and in full force and effect. Offerors must acknowledge this Amendment #2, by acknowledging receipt of the amendment on each copy of the offer submitted. Failure to receive your acknowledgment of this amendment may result in the rejection of your offer.